Blue Dart, which is part-owned by Deutsche Post DHL (DPDH) Group, is working closely with the pharma sector to prepare for a Covid-19 vaccine.
In a statement the India-based express firm said that it is actively working with pharmaceutical organisations as the development of a Covid-19 vaccine continues.
Blue Dart has successfully tailored its existing temperature controlled logistics (TCL) solution to transport critical shipments such as vaccines, medical samples and more. The TCL teams work with three industry specific segments: Clinical research organisations (CRO), vaccine/testing kit manufactures and active pharma ingredients for swift and safe delivery of shipments.
Ketan Kulkarni, head of business development, Blue Dart, commented: “The right partnerships are vital to secure critical medical supplies during health emergencies. We are actively working with various pharmaceutical organizations that are conducting clinical trials to produce a Covid-19 vaccine in India in their pre and post production journey.
“As a part of the DPDHL Group, Blue Dart has the knowhow of the internal best practices in the life sciences and healthcare logistics business and is a part of a large global logistics network which allows us to use each of our sister Business Unit’s strength in providing the best solution to our customer.”
Blue Dart has continuously worked with the medical equipment and pharmaceuticals sector to maintain the supply chain and deliver critical shipment and essential supplies including Covid vaccine samples, temperature-controlled movement of COVID-19 testing kits, ventilators, PPE, testing kits, reagents, enzymes, respirators, surgical masks, goggles and gloves amongst other critical material.
The company’s six Boeing 757 freighters ensure the ease in ramping up operations swiftly to handle large scale shipments.